Lonza offloads specialty ingredients unit in $4.7B sale to Bain Capital, Cinven in consolidation around biopharma
With the biopharma CDMO market on a yearslong upswing, giant Lonza has looked to rework the game plan to keep its golden goose productive. After …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
